Advertisement

Search Results

Advertisement



Your search for can matches 13492 pages

Showing 8651 - 8700


head and neck cancer

Particular HPV Strain Linked to Improved Prognosis for Oropharyngeal Cancer

When it comes to cancer-causing viruses like human papillomavirus (HPV), researchers are continuing to find that infection with one strain may be better than another. In an analysis of survival data for patients with oropharyngeal cancer, researchers from the University of North Carolina (UNC)...

bladder cancer

Development and Validation of a Quality Assurance Score for Robot-Assisted Radical Cystectomy

What are the factors that add up to the best outcomes for patients who have surgery to treat cancer? Looking for a better way to measure quality of care and share best practices in surgical oncology, a team from Roswell Park Cancer Institute developed a quality assessment tool and validated it in a ...

pain management
survivorship

A Helping Hand, Just in Time: The ASCO Guideline for Managing Chronic Pain in Adult Cancer Survivors

With impeccable timing, as well as considerable forethought and planning, Dr. Paice and colleagues have produced a superb evidence-based guideline on “Management of Chronic Pain in Survivors of Adult Cancers.”1 (See this issue of The ASCO Post.) This summary of well-informed and thoroughly...

pain management
survivorship

ASCO Clinical Practice Guideline on Management of Chronic Pain in Survivors of Adult Cancers

As reported in the Journal of Clinical Oncology by Judith A. Paice, PhD, RN, of Northwestern University, and colleagues, ASCO has released a clinical practice guideline on management of chronic pain in survivors of adult cancers.1 The guideline was based on literature review by an expert panel,...

lung cancer

Small Cell Lung Cancer and Immunotherapy: A Change Is Coming, Just Not Front Line (Yet!)

Ever since the immune checkpoint agents arrived, the pace of clinical investigation in oncology has continued to accelerate with an ever-increasing number of trials of single-agent and combination therapies with novel designs that are transforming our drug-development process. However, even in...

cns cancers

Which Factors Influence Radiotherapy for Brain Metastases?

The advent of more effective systemic therapies, which extend patients’ lives, has also resulted in an increasing incidence of brain metastases, for which clinicians must determine appropriate treatment. Whole-brain radiotherapy has been the traditional treatment modality, but stereotactic...

New Edition of The MD Anderson Manual of Medical Oncology

The third edition of The MD Anderson Manual of Medical Oncology was recently published, offering detailed updates on the personalized multidisciplinary approach to cancer management and treatment of common and rare cancers by specialists at The University of Texas MD Anderson Cancer Center. The...

Friends of Cancer Research Honors Oncology Leaders at 20th Anniversary and Announces Partnership

Friends of Cancer Research (Friends) celebrated its 20th anniversary September 21 at a special event in Washington, DC. The event honored Janet Woodcock, MD; Eric Lander, PhD; and Sean Parker. Dr. Woodcock, Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug...

genomics/genetics

Using Watson to Analyze Genomic Data to Personalize Treatment for Patients With Cancer

Three years ago, IBM’s Watson supercomputer was best known for defeating two former champions on the TV game show Jeopardy! Today, it is grabbing headlines for becoming an important assistant in cancer care. Able to read and understand millions of pages of text within seconds, Watson caught the...

multiple myeloma

Daratumumab Plus Bortezomib/Dexamethasone: Changing the Treatment Paradigm in Relapsed or Refractory Myeloma

The CD38 antigen was first recognized on normal and abnormal plasma cells over 3 decades ago. Indeed, this antigen was originally classified as T10, as it was the tenth antigen described on T cells. Its distribution of expression included activated B and T cells, natural killer cells, leukocytes,...

breast cancer

Susan G. Komen Announces $27 Million Initiative to Reduce Breast Cancer Deaths in African American Community

The Susan G. Komen breast cancer organization gathered philanthropic, civic, medical, and business leaders in Washington, DC, September 14 to formally launch a $27 million, 10-city initiative to reduce breast cancer death rates among African American women. “African American women are almost 40%...

Internationally Renowned Statistician on Cancer Clinical Trials, Daniel J. Sargent, PhD, Dies

In the 20th century, the field of statistics developed and was gradually applied to clinical research. The use of statistics allows clinical researchers to form reasonable and accurate inferences from collected information and to make sound decisions in the presence of uncertainty. Moreover,...

issues in oncology
supportive care
palliative care

Why Care About the Caregivers?

Caregivers of patients with cancer provide invaluable health-care services, but they are an underserved and undervalued group, with many unmet needs. Early palliative care may provide important benefits to these often tireless individuals, according to J. Nicholas Dionne-Odom, PhD, RN, ACHPN, of...

palliative care

Benefits of Early Palliative Care Interventions Extend Beyond the Patient

A session at the 2016 Palliative Care in Oncology Symposium focused on the special needs of cancer caregivers. In a large survey, caregivers of persons with cancer reported higher levels of stress and significantly more duties than caregivers of other patients. But, according to research from...

palliative care

Palliative Care: Let’s Use the Tools We Already Have

Clinicians and researchers in the field of palliative and supportive care are enjoying the recognition the field is now receiving and expecting the future to be ripe with opportunity. But one thought leader in this specialty had a suggestion for attendees at the 2016 Palliative Care in Oncology...

symptom management
palliative care

Pearls for Managing Immune-Related Toxicities

With checkpoint inhibitors in frequent use, clinicians strive daily to balance the efficacy and toxicity of these treatments. At the 2016 Palliative Care in Oncology Symposium, Lynn M. Schuchter, MD, FASCO, the C. Willard Professor of Hematology-Oncology at the University of Pennsylvania,...

issues in oncology
palliative care

Immunotherapy Brings Unique Challenges for Clinicians

The advent of immunotherapies has created a number of interesting challenges for oncology providers. At the 2016 Palliative Care in Oncology Symposium, specialists in the field tackled these issues. “There is a lot of newness to how we approach patient care with immunotherapies on board,” said...

issues in oncology
health-care policy
survivorship

Why Curing Cancer Will Take Decades

This past summer, Eric S. Lander, PhD, President of the Broad Institute of the Massachusetts Institute of Technology and Harvard in Cambridge, Massachusetts, and Co-Chair of the President’s Council of Advisors on Science and Technology, raised a few eyebrows at the Aspen Ideas Festival when he...

palliative care

Bridging the Gap in Oncology Care

The third annual Palliative Care in Oncology Symposium, held on September 9–10, 2016, in San Francisco, California, brought together more than 650 attendees from multiple countries, including the United States, Canada, the United Kingdom, France, Italy, and China. It featured over 250 study...

health-care policy
issues in oncology

COA Releases 2016 Community Oncology Practice Impact Report

The Community Oncology Alliance (COA) released the 2016 Community Oncology Practice Impact Report today, which tracks the changing landscape of cancer care in the United States. It documents a 121% increase in community cancer clinic closings and a 172% increase in consolidation into hospitals...

ASCO Presents First-Ever Congressional Leadership Award to Rep. Michael Burgess, MD

ASCO presented Representative Michael Burgess, MD (TX-26) with its first-ever ASCO Congressional Leadership Award on September 21 to recognize his steadfast work to support policies related to cancer research and treatment. This new, annual award honors a member of Congress who is a consistent...

hematologic malignancies

Update on Neoplastic Hematology: Review of Recent Clinical Trials

Here is a brief look at the study findings and clinical implications of several recent clinical trials on newer treatment options in neoplastic hematology. Attention is focused on several types of leukemia, Hodgkin lymphoma, and multiple myeloma. Leukemia Clinical Trial: INO-VATE ALL phase III...

Salk Institute’s Clodagh O’Shea, PhD, Named Howard Hughes Medical Institute Faculty Scholar

Clodagh O’Shea, PhD, Associate Professor in the Salk Institute’s Molecular and Cell Biology Laboratory, is among the first recipients of a grant from the Faculty Scholars Program, a new partnership of Howard Hughes Medical Institute (HHMI), the Bill and Melinda Gates Foundation, and the Simons...

global cancer care

Baylor and Texas Children’s Hospital Partner to Bring Fellowship Training in Oncology and Hematology to East Africa

Medical students and practicing pediatricians in Uganda and other East African countries lack access to specialty pediatric training and education in oncology and hematology in their region, despite the need for doctors to provide care for patients with cancer and blood disorders. A new program of...

lung cancer
issues in oncology

ASTRO 2016: Intervention Closes Racial Gap and Improves Treatment Rates for Early-Stage Lung Cancer

Enhanced, culturally competent communication with early-stage lung cancer patients can narrow racial gaps in curative treatment completion and increase treatment rates for all races, according to research presented by Manning et al at the 58th Annual Meeting of the American Society for Radiation...

cns cancers

ASTRO 2016: Stereotactic Radiosurgery Decreases Rate of Postoperative Local Recurrence for Brain Metastases

Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence, but shows no positive difference in terms of overall survival or distant brain metastases rates when compared to observation alone following surgical...

prostate cancer

ASTRO 2016: SBRT Offers Patients With Prostate Cancer High Disease Control and Low Toxicity in Fewer Treatments

High-dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates, according to research presented by Meier et al at the 58th Annual Meeting of the...

lung cancer

ASTRO 2016: Hypofractionated Radiation Therapy May Halve Treatment Time for Lung Cancer Patients With Poor Performance Status

For patients with stage II and III non–small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation, hypofractionated radiation therapy results in similar overall survival and progression-free survival rates, limited severe side effects, and shorter...

cns cancers

ASTRO 2016: Reduced Radiation Boost Volume Recommended for Average-Risk Pediatric Medulloblastoma, but Craniospinal Axis Dose Remains Unchanged

In the largest trial conducted for average-risk medulloblastoma, survival rates following reduced radiation therapy boost volumes were comparable to standard treatment volumes for the primary tumor site, but lower doses of craniospinal axis irradiation were associated with higher event rates and...

cns cancers

ASTRO 2016: Postoperative Stereotactic Radiosurgery: New Standard of Care for Patients With Resected Brain Metastases?

For patients who have cancer that has metastasized to the brain, stereotactic radiosurgery (SRS) results in statistically comparable survival rates, reduced cognitive decline, and better quality of life, compared to whole-brain radiotherapy (WBRT), according to research presented at the 58th Annual ...

prostate cancer

ASTRO 2016: Three Novel Intrinsic Subtypes of Prostate Cancer Identified

In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research...

lung cancer

ASTRO 2016: Advances in Radiation Therapy Have Improved Survival Rates for Patients With Early-Stage Lung Cancer

A new analysis of records in the Veterans Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non–small cell lung cancer (NSCLC) in recent years, according to research presented...

prostate cancer

ASTRO 2016: Intermediate-Risk Prostate Cancer May Be Well Controlled With Brachytherapy Alone

For men with intermediate-risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research...

breast cancer

ASCO/ASTRO/SSO Develop Focused Guideline Update on Postmastectomy Radiotherapy

As reported by Recht et al in the Journal of Clinical Oncology, a joint ASCO, American Society for Radiation Oncology (ASTRO), and Society of Surgical Oncology (SSO) panel has developed a focused guideline update of the ASCO guideline on postmastectomy radiotherapy. A recent Cancer Care Ontario...

issues in oncology
global cancer care

ASTRO 2016: Unmet Need for Radiation Therapy Found Among Nearly Half of Eligible Cancer Patients in Nine Developing Countries

Although approximately 50% of cancer patients in developing countries need radiation therapy to treat their disease, up to half of these patients do not have access to it, according to research presented by Rosenblatt et al at the 58th Annual Meeting of the American Society for Radiation Oncology...

prostate cancer

ASTRO 2016: Hypofractionated Radiation Therapy Can Reduce Treatment Time With Comparable Quality of Life for Patients With Prostate Cancer

For men with early stage, low-risk prostate cancer, treatment with hypofractionated radiation therapy offers comparable health-related quality of life outcomes in one-third less treatment time than conventional radiation therapy, according to research presented by Watkins Bruner et al at the 58th...

lung cancer

ASTRO 2016: Widespread Adoption of SBRT Has Improved Survival Rates for Elderly Patients With Early-Stage Lung Cancer

Survival rates for elderly patients who received stereotactic body radiation therapy (SBRT) for early stage non–small cell lung cancer (NSCLC) rose from roughly 40% to 60% over the past decade, concurrent with the increasing adoption of SBRT, according to research presented by Dalwadi et al...

gynecologic cancers

ASTRO 2016: Cervical and Endometrial Cancer Patients Report Fewer Side Effects and Better Quality of Life With IMRT

Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience better quality of life when treated with intensity-modulated radiation therapy (IMRT) than with conventional radiation therapy, according to research presented by Klopp et al at...

skin cancer

Ratio of Certain Immune Cells in the Blood to Tumor Burden Correlated With Outcome for Melanoma Patients Treated With Pembrolizumab

Although some patients with melanoma experience durable responses to treatment with the anti–PD-1 (programmed cell death protein 1) therapy pembrolizumab (Keytruda), the majority of patients do not experience a durable clinical benefit from anti–PD-1 monotherapy, according to a study by ...

head and neck cancer

Addition of CHK1 Inhibitor Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy

Combining a new targeted drug that blocks one of cancer’s escape routes could boost the effectiveness of combined chemoradiotherapy for head and neck cancers and stop cells becoming resistant to treatment. Researchers at The Institute of Cancer Research, London (ICR), and The Royal Marsden...

prostate cancer

Blood Biomarkers in Abiraterone- or Enzalutamide-Resistant Prostate Cancer Tumor Cells 

While searching for a noninvasive way to detect prostate cancer cells circulating in blood, Duke Cancer Institute researchers have identified some blood markers associated with tumor resistance to two common hormone therapies. In a study published by Gupta et al in Clinical Cancer Research, a team...

Saul J. Sharkis, PhD, Stem Cell Researcher, Dies

Saul J. Sharkis, PhD, a scientist who studied the biology of blood stem cells and how they could be used to treat cancer through bone marrow transplantation, died on September 4. He was 72. Dr. Sharkis was Professor of Oncology at the Johns Hopkins University School of Medicine and a faculty...

Emily L. Sedgwick, MD, Receives Ben and Margaret Love Foundation Bobby Alford Award for Academic Clinical Professionalism

Emily L. Sedgwick, MD, Associate Professor of Breast Imaging in the Lester and Sue Smith Breast Center, part of the National Cancer Institute–designated Dan L. Duncan Comprehensive Cancer Center, has been named the 2016 recipient of the Ben and Margaret Love Foundation Bobby Alford Award for...

kidney cancer
breast cancer

I’ve Survived Cancer for Over 71 Years

Even though I was just 3 years old when my symptoms first appeared, the memory is still fresh in my mind to this day, 71 years later. I had just come home from a friend’s birthday party and was sitting on the front patio steps immobilized by severe stomach pain. My parents said I was feeling ill...

gynecologic cancers

An Ovarian Cancer Expert’s Guide Offers Insight, Wisdom, and Hope

There have been numerous books explicating the information a physician or patient needs to know about our current clinical state in the diagnosis and treatment of ovarian cancer. Many of them are good, but rare is a well-written book in the cancer genre that offers solid scientific hope exceeding ...

Cancer Moonshot Blue Ribbon Panel Recommends 10 Ways to Speed Cancer Advances

Earlier this month, members of the National Cancer Moonshot Initiative’s Blue Ribbon Panel submitted an ambitious list of 10 recommendations on the scientific approaches that are most likely to accelerate progress against cancer to the President’s National Cancer Advisory Board. The panel’s...

issues in oncology
genomics/genetics

Psychological Impact of Genetic Testing to Be Explored in Subset of NCI-MATCH Trial Patients

The Eastern Cooperative Oncology Group–American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group has received federal approval to add a quality-of-life research study, Communication and Education in Tumor Profiling (EAQ152), or COMET, to the NCI-MATCH (EAY131) trial, which is ...

2016 Lasker Awards Honor Scientists for Basic and Clinical Medical Research, Special Achievement

The Albert and Mary Lasker Foundation has announced the winners of the 2016 Lasker Awards for medical science: William G. ­Kaelin, MD; ­Peter J. Ratcliffe, MD, FRCP, FMedSci, FRS; and Gregg L. ­Semenza, MD, PhD for basic medical research; Ralf F.W. Bartenschlager, PhD; Charles M. Rice, PhD;...

issues in oncology

The Halifax Project: A New Approach to Combination Therapy

On August 13, 2013, more than 100 cancer researchers and physicians from around the world met in Halifax, Nova Scotia, Canada, to discuss 2 challenging problem areas in cancer. One group was focused on the carcinogenic potential of low-dose exposure to chemical mixtures in the environment, and the...

issues in oncology

Recognizing the Unique Experiences of Cancer Among Adolescent and Young Adult Survivors

Studies show that adolescent and young adult cancer survivors experience distinct challenges and quality-of-life issues from those experienced by either younger or older adult cancer survivors and that those challenges and issues can persist long after the cancer diagnosis and the end of...

Advertisement

Advertisement




Advertisement